The skin changes that accompany menopause are structural, not cosmetic. Declining estrogen does not simply thin the skin — it changes how the skin produces collagen, retains water, repairs damage, and maintains its barrier. These changes follow menopausal age, not chronological age. A woman who enters menopause at 45 and a woman who enters at 55 will show similar skin changes relative to their menopause onset, not their birth year.
The aesthetic-medicine conversation around menopause has accelerated sharply. A 2026 global survey by Galderma of over 4,300 peri- and post-menopausal women across nine countries, presented at IMCAS 2026, found that over 50% learned about menopause's skin effects by going through them — not before. Over 60% said they would have acted differently with earlier knowledge. The same survey found that 47% would consider anti-wrinkle treatment, 41% hyaluronic acid treatment, and 30% biostimulators.
This article covers what happens to skin during menopause, what the evidence says about hormonal and aesthetic interventions, and which treatments have actual clinical data in menopausal populations.
What estrogen does in the skin
Estrogen acts on fibroblasts through estrogen receptors in the dermis. It stimulates the production of type I collagen (which provides structural strength) and type III collagen (which contributes to elasticity). It also promotes hyaluronic acid synthesis, supports the skin barrier, improves blood flow, and aids wound healing.
When estrogen declines during perimenopause and menopause, all of these processes slow. The result is thinner skin, reduced elasticity, decreased hydration, slower wound repair, and increased susceptibility to trauma and bruising. These changes compound year over year.
The collagen numbers
The foundational research comes from Brincat and colleagues, whose observational and histologic studies beginning in the 1980s documented:
- 30% collagen loss in the first 5 years after menopause — both type I and type III collagen. This is the figure most widely cited in the literature and has been confirmed across multiple subsequent studies.
- 2.1% per year additional collagen loss over at least 15 postmenopausal years — this is a sustained decline after the initial sharp drop.
- 1.13% per year decrease in skin thickness during the first 19 postmenopausal years.
- 1.5% per year decline in skin elasticity, accompanied by increased distensibility (1.1% per year) and viscosity (1.3% per year).
These are not theoretical projections. They are drawn from skin biopsies and measurement studies comparing postmenopausal women at different stages, with and without hormone replacement therapy (HRT). The collagen loss correlates with menopausal age, not chronological age — meaning a 50-year-old who has been postmenopausal for 5 years has less collagen than a 50-year-old who is still cycling.
The net effect: a woman who reaches menopause at 51 may have lost over 60% of her skin collagen by age 66 without intervention.
Skin changes menopausal women actually notice
The clinical presentation is often described as "accelerated aging" because the changes can seem sudden. The most common complaints:
- Dryness and barrier dysfunction. Reduced hyaluronic acid and glycosaminoglycan production lead to decreased water-holding capacity. The skin feels dry, tight, and sometimes irritated by products that previously caused no issues.
- Volume loss and laxity. Collagen loss produces visible thinning, especially in the face, neck, and hands. Cheeks flatten, nasolabial folds deepen, and the jawline softens.
- Wrinkling. Reduced dermal thickness and elasticity produce finer lines that progress to deeper wrinkles, particularly in sun-exposed areas. A 2004 study by Sumino et al. found that HRT reduced wrinkle depth by 30–40% after one year, suggesting that much of the wrinkling is hormonally driven.
- Increased fragility. Thinner skin bruises more easily, tears more easily, and heals more slowly. This is not vanity — it is a functional change that affects quality of life.
- Texture changes. The skin surface may appear crepey or rough, especially on the neck, chest, and hands.
Hormone replacement therapy and the skin
HRT is the only intervention that addresses the underlying hormonal driver of menopausal skin changes. The evidence is consistent across decades of research:
- A 1987 randomized, double-blind, placebo-controlled study of conjugated equine estrogen (CEE) in 60 postmenopausal women found a 30% increase in dermal thickness after 1 year.
- Brincat et al. found a 48% increase in skin collagen content in women treated with subcutaneous estradiol and testosterone for 2–10 years compared to untreated controls.
- A 6-month study of systemic HRT found a 6.49% increase in dermal collagen (p = 0.05).
- A study of transdermal estradiol found topical estradiol produced a 38% increase in total collagen over 3 months in treated skin areas.
- Maheux et al. reported a 33% increase in dermal thickness after 6 months of oral CEE in a double-blind, placebo-controlled trial.
- Research has shown that women with HRT history had up to 79% lower risk of facial wrinkling compared to non-users.
The limitation: HRT is a systemic treatment with risks and contraindications that must be evaluated individually. The decision to use HRT involves considerations beyond skin — cardiovascular health, breast cancer risk, thromboembolism history, and personal risk factors. HRT is not prescribed solely for skin benefits, and the skin effects should not drive the HRT decision independently.
A 2025 narrative review in the Journal of Cosmetic Dermatology concluded that "minimal invasive aesthetic treatment could add value to this patient group" alongside HRT — positioning aesthetic treatments as complementary, not alternative, to hormonal management.
Aesthetic treatments for menopausal skin: what the evidence shows
Biostimulators (Sculptra / poly-L-lactic acid, hyper-diluted CaHA)
Biostimulators are increasingly positioned as the primary aesthetic tool for menopausal skin because they address the root pathology — collagen loss — by stimulating new collagen production rather than simply filling volume.
- Sculptra (PLLA): Galderma presented interim data at IMCAS 2026 from an investigator-initiated trial specifically studying Sculptra in menopausal patients. The trial is evaluating skin quality improvements including hydration and collagen-related parameters, with early results described as "meaningful improvements in skin hydration and collagen-related skin quality over time" alongside "rising patient satisfaction."
- Hyper-diluted CaHA (Radiesse): A 2025 narrative review noted that hyper-diluted calcium hydroxylapatite, when diluted with lidocaine or saline, has demonstrated stimulation of collagen and elastin synthesis, increased neovascularization, and improvements in dermal thickness, elasticity, and pliability — particularly in the neck and décolletage — without a volumizing effect.
Biostimulators are not reversible. They work gradually over weeks to months. This aligns well with the menopausal timeline — the collagen loss is gradual, and the replacement can be too. But it also means that if the result is unsatisfactory, there is no hyaluronidase-equivalent to dissolve it.
Hyaluronic acid skin boosters
- Restylane Skinboosters: The same Galderma investigator-initiated trial is also evaluating Restylane Skinboosters (hyaluronic acid skin-quality injections) in menopausal patients. HA skin boosters address the hydration and barrier-function aspects of menopausal skin rather than the collagen deficit. They provide immediate hydration by attracting and holding water in the dermis.
- A separate clinical trial (NCT07205744, "Advancing Post-Menopausal Skin Health") registered in January 2026 is comparing Restylane SkinBoosters Vital and Sculptra Aesthetic head-to-head in postmenopausal women, with primary outcomes of skin hydration and elasticity, and secondary outcomes examining whether HRT influences the effectiveness of either treatment.
This is a meaningful development: most aesthetic treatments have not been specifically studied in menopausal populations. The fact that these trials exist at all reflects the growing recognition that menopausal skin may respond differently than younger skin to the same treatments.
Energy-based devices
- Microfocused ultrasound (MFU-V, e.g., Ultherapy): The 2025 narrative review noted that MFU-V targets the SMAS and platysma layers to induce tissue tightening and lifting — addressing laxity rather than collagen quantity. This is relevant for menopausal patients whose primary concern is sagging rather than volume loss.
- Fractional laser and RF microneedling: These devices can improve texture, stimulate collagen, and address surface irregularities. However, menopausal skin may be more susceptible to prolonged redness, dryness, and barrier disruption after energy treatments due to reduced healing capacity. The evidence for specific benefit in menopausal patients is indirect — drawn from general aging-skin studies rather than menopause-specific trials.
Topical retinoids
Retinoids (tretinoin, adapalene, retinaldehyde) remain the most evidence-based topical for collagen stimulation. The 2025 narrative review acknowledged their role in stimulating collagen production and improving skin texture. For menopausal patients, the considerations are:
- Barrier sensitivity. Menopausal skin is more prone to irritation. Gradual introduction and buffering may be necessary.
- Dryness interaction. Retinoids can worsen dryness, which is already a primary complaint in menopausal skin. Concurrent use of barrier-repair moisturizers is important.
- Sun sensitivity. Menopausal skin that is thinner and more fragile may be more susceptible to UV damage, compounding the photosensitizing effect of retinoids.
What is not well established
- Exosomes, PRP, and PDRN for menopausal skin specifically lack robust trial data in this population. The general anti-aging evidence is reviewed in the AestheticMedGuide article on PDRN vs PRP vs exosomes, but menopause-specific outcome data is not yet available.
- Oral collagen supplements have mixed evidence overall and no menopause-specific trial data that demonstrates meaningful collagen restoration in postmenopausal skin.
- The question of prevention vs. treatment. The Galderma global survey found that women currently use aesthetics primarily as treatment (49%) rather than prevention (26%), largely because they did not know about menopausal skin effects until they were experiencing them. Whether earlier aesthetic intervention in perimenopause produces meaningfully better outcomes than later treatment has not been studied.
How to think about sequencing
There is no single correct sequence for treating menopausal skin. The approach depends on what is most bothersome to the patient and what is medically appropriate:
- If the patient is open to HRT and medically appropriate, systemic hormone therapy addresses the underlying driver and produces measurable skin improvements. This is a conversation with a gynecologist or endocrinologist, not an aesthetic provider.
- For collagen restoration, biostimulators (Sculptra, hyper-diluted CaHA) have the most direct mechanism of action and emerging menopause-specific evidence.
- For hydration and barrier function, HA skin boosters address the dryness and water-retention deficit that menopausal skin produces.
- For laxity, MFU-V or RF-based tightening addresses the mechanical sagging that collagen loss produces.
- For texture and surface quality, topical retinoids (with appropriate barrier support) and fractional laser or RF microneedling address roughness, crepiness, and fine lines.
- For volume loss in specific areas, HA fillers provide immediate structural support — but they do not replace the collagen that menopause is taking away.
The most effective approach is often a combination of several of these, layered over time. The emerging clinical data on dual-sequencing (e.g., the Galderma trial studying both Restylane Skinboosters and Sculptra in menopausal patients) is beginning to provide evidence for how these treatments interact.
What to ask a provider
Menopausal skin is not simply "aging skin." It is hormonally depleted skin with a distinct set of structural changes. A provider who treats menopausal patients should be able to:
- Distinguish between collagen-loss-related changes and sun-damage-related changes, since the treatment approach differs.
- Discuss HRT as an option (or refer to someone who can), rather than positioning aesthetic treatments as a replacement for hormonal management.
- Explain which treatments have specific evidence in menopausal populations and which are being recommended based on general anti-aging data.
- Account for the increased barrier sensitivity, dryness, and healing-capacity reduction that menopausal skin brings when recommending energy-based treatments or topical regimens.
Sources
- Brincat M, Muscat Baron Y, Galea R. "Estrogens and the skin." Climacteric. 2005;8(2):110-123. Available at: https://pubmed.ncbi.nlm.nih.gov/16096167/
- Brincat M, Versi E, Moniz CF, et al. "Skin collagen changes in postmenopausal women receiving different regimens of estrogen therapy." Obstet Gynecol. 1987;70:123-127.
- Managing Menopausal Skin Changes: A Narrative Review. Journal of Cosmetic Dermatology. 2025. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12374573/
- Galderma global survey on menopause skin changes, presented at IMCAS 2026. Available at: https://www.galderma.com/news/galderma-tackles-menopause-related-skin-changes
- Galderma interim trial data on Restylane Skinboosters and Sculptra in menopausal patients. Available at: https://www.galderma.com/news/interim-data-two-ongoing-investigator-initiated-trials-highlight-role-sculptra-and-restylane
- Clinical trial NCT07205744: "Advancing Post-Menopausal Skin Health." Available at: https://ichgcp.net/clinical-trials-registry/555323-post-menopause-skin-rejuvenation-study
- Sumino H, et al. "Effects of hormone replacement therapy on skin." J Am Geriatr Soc. 2004.
- Caliens C, et al. "Skin changes in menopause." Maturitas. 1996.
- Shuster S, Black MM, McVitie E. "The influence of age and sex on skin thickness, skin collagen and density." Br J Dermatol. 1975;93:639-643.
